COO The Cooper Companies, Inc.
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About The Cooper Companies (NASDAQ: COO)
›
The Cooper Companies (NASDAQ: COO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 15,000 employees.
The shares were at 62.65 USD on 13 November 2026, down 13.6% over 52 weeks. Its 52-week range is 51.01 USD to 89.83 USD: the price is 30.3% below the high and 22.8% above the low.
At a market capitalisation of 11.91B USD, it trades at 21.5 times trailing earnings and 13.4 times forward earnings. The median trailing P/E of its 18 largest Medical Instruments & Supplies peers is 53.9, a discount of 60% for COO.
The Cooper Companies reports return on equity of 4.6%, an operating margin of 12.9% and revenue up 0.6% year over year.
Its debt exceeds its cash by 2.65B USD, a debt-to-equity ratio of 0.30. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 15 analysts cover the stock, with an average rating of Hold; their mean price target of 65.80 USD is 5.0% above the current price. The next earnings report is expected on 3 December 2026.